RCT: Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis.
10 Mar, 2022 | 10:27h | UTCComparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial – The Lancet Rheumatology (link to abstract – $ for full-text)
Commentary: COMPLETE-PsA: Adding leflunomide to methotrexate may improve outcomes – medwireNews
Commentary on Twitter
NEW RESEARCH—A double-blind, placebo-controlled, randomised, trial comparing #methotrexate monotherapy with methotrexate plus #leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA) https://t.co/Fln7RlNl36 #LancetRheumatology pic.twitter.com/EqWSeHZQA2
— The Lancet Rheumatology (@TheLancetRheum) March 3, 2022